株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

大腸癌:パイプライン製品の分析

Colorectal Cancer - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232768
出版日 ページ情報 英文 1564 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
大腸癌:パイプライン製品の分析 Colorectal Cancer - Pipeline Review, H1 2016
出版日: 2016年06月30日 ページ情報: 英文 1564 Pages
概要

大腸癌は、結腸または直腸から発生し始める癌で、その症状には、下痢や便秘、血便、激しい腹痛、満腹感や膨満感、原因不明の体重減、倦怠感、悪心、嘔吐などがあります。大腸癌を罹患する原因としては、喫煙、2型糖尿病、大腸癌を発症しやすい家系などが挙げられます。

当レポートでは、大腸癌治療薬におけるパイプライン製品の概要や治験の段階別の製品概要、主要企業のプロファイル、薬剤のプロファイル、パイプライン製品の最新動向などを提供しています。

イントロダクション

  • 調査範囲

大腸癌の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

大腸癌:企業で開発中の治療薬

大腸癌:大学/機関で研究中の治療薬

大腸癌:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

大腸癌:企業で開発中の製品

大腸癌:大学/機関で研究中の製品

大腸癌の治療薬開発に従事している企業

大腸癌:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

大腸癌:休止中のプロジェクト

大腸癌:開発が中止された製品

大腸癌:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7959IDB

Summary

Global Markets Direct's, 'Colorectal Cancer - Pipeline Review, H1 2016', provides an overview of the Colorectal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Colorectal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Colorectal Cancer
  • The report reviews pipeline therapeutics for Colorectal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Colorectal Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Colorectal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Colorectal Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Colorectal Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Colorectal Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Colorectal Cancer Overview
  • Therapeutics Development
  • Colorectal Cancer - Therapeutics under Development by Companies
  • Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes
  • Colorectal Cancer - Pipeline Products Glance
  • Colorectal Cancer - Products under Development by Companies
  • Colorectal Cancer - Products under Investigation by Universities/Institutes
  • Colorectal Cancer - Companies Involved in Therapeutics Development
  • Colorectal Cancer - Therapeutics Assessment
  • Drug Profiles
  • Colorectal Cancer - Dormant Projects
  • Colorectal Cancer - Discontinued Products
  • Colorectal Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Colorectal Cancer, H1 2016
  • Number of Products under Development for Colorectal Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Development by Companies, H1 2016 (Contd..10)
  • Number of Products under Development by Companies, H1 2016 (Contd..11)
  • Number of Products under Development by Companies, H1 2016 (Contd..12)
  • Number of Products under Development by Companies, H1 2016 (Contd..13)
  • Number of Products under Development by Companies, H1 2016 (Contd..14)
  • Number of Products under Development by Companies, H1 2016 (Contd..15)
  • Number of Products under Development by Companies, H1 2016 (Contd..16)
  • Number of Products under Development by Companies, H1 2016 (Contd..17)
  • Number of Products under Development by Companies, H1 2016 (Contd..18)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Development by Companies, H1 2016 (Contd..14)
  • Products under Development by Companies, H1 2016 (Contd..15)
  • Products under Development by Companies, H1 2016 (Contd..16)
  • Products under Development by Companies, H1 2016 (Contd..17)
  • Products under Development by Companies, H1 2016 (Contd..18)
  • Products under Development by Companies, H1 2016 (Contd..19)
  • Products under Development by Companies, H1 2016 (Contd..20)
  • Products under Development by Companies, H1 2016 (Contd..21)
  • Products under Development by Companies, H1 2016 (Contd..22)
  • Products under Development by Companies, H1 2016 (Contd..23)
  • Products under Development by Companies, H1 2016 (Contd..24)
  • Products under Development by Companies, H1 2016 (Contd..25)
  • Products under Development by Companies, H1 2016 (Contd..26)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Colorectal Cancer - Pipeline by 2cureX ApS, H1 2016
  • Colorectal Cancer - Pipeline by 3-V Biosciences, Inc., H1 2016
  • Colorectal Cancer - Pipeline by 4SC AG, H1 2016
  • Colorectal Cancer - Pipeline by AB Science SA, H1 2016
  • Colorectal Cancer - Pipeline by AbbVie Inc., H1 2016
  • Colorectal Cancer - Pipeline by AbGenomics International, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Adamed Sp. z o.o., H1 2016
  • Colorectal Cancer - Pipeline by Advaxis, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016
  • Colorectal Cancer - Pipeline by Alchemia Limited, H1 2016
  • Colorectal Cancer - Pipeline by Allinky Biopharma, H1 2016
  • Colorectal Cancer - Pipeline by Amal Therapeutics SA, H1 2016
  • Colorectal Cancer - Pipeline by Amgen Inc., H1 2016
  • Colorectal Cancer - Pipeline by Antibe Therapeutics, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Apac Biotech Pvt Ltd, H1 2016
  • Colorectal Cancer - Pipeline by Apexigen, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Aphios Corporation, H1 2016
  • Colorectal Cancer - Pipeline by Aposense Ltd., H1 2016
  • Colorectal Cancer - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2016
  • Colorectal Cancer - Pipeline by ArQule, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Array BioPharma Inc., H1 2016
  • Colorectal Cancer - Pipeline by Astellas Pharma Inc., H1 2016
  • Colorectal Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2016
  • Colorectal Cancer - Pipeline by AstraZeneca Plc, H1 2016
  • Colorectal Cancer - Pipeline by ATLAB Pharma SAS, H1 2016
  • Colorectal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Basilea Pharmaceutica AG, H1 2016
  • Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H1 2016
  • Colorectal Cancer - Pipeline by Bayer AG, H1 2016
  • Colorectal Cancer - Pipeline by BeiGene, Ltd., H1 2016
  • Colorectal Cancer - Pipeline by Biocon Limited, H1 2016
  • Colorectal Cancer - Pipeline by Bionomics Limited, H1 2016
  • Colorectal Cancer - Pipeline by Bionovis SA, H1 2016
  • Colorectal Cancer - Pipeline by Biotecnol, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Colorectal Cancer - Pipeline by Boston Biomedical, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Colorectal Cancer - Pipeline by Burzynski Research Institute, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Calithera Biosciences, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Carna Biosciences, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Cascadian Therapeutics Inc, H1 2016
  • Colorectal Cancer - Pipeline by CCRP Therapeutics GmbH, H1 2016
  • Colorectal Cancer - Pipeline by Celator Pharmaceuticals, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Celgene Corporation, H1 2016
  • Colorectal Cancer - Pipeline by Cellceutix Corporation, H1 2016
  • Colorectal Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Cellectar Biosciences, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Celltrion, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Chiome Bioscience, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2016
  • Colorectal Cancer - Pipeline by Cipla Ltd., H1 2016
  • Colorectal Cancer - Pipeline by Cleave Biosciences, H1 2016
  • Colorectal Cancer - Pipeline by Cleveland BioLabs, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Clonz Biotech Private Limited, H1 2016
  • Colorectal Cancer - Pipeline by Coare Biotechnology, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Coherus BioSciences, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Corvus Pharmaceuticals, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016
  • Colorectal Cancer - Pipeline by CritiTech, Inc., H1 2016
  • Colorectal Cancer - Pipeline by CrystalGenomics, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Cytune Pharma SAS, H1 2016
  • Colorectal Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Colorectal Cancer - Pipeline by DanDrit Biotech A/S, H1 2016
  • Colorectal Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016
  • Colorectal Cancer - Pipeline by Delcath Systems, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016
  • Colorectal Cancer - Pipeline by Digna Biotech, S.L., H1 2016
  • Colorectal Cancer - Pipeline by Double Bond Pharmaceutical International AB, H1 2016
  • Colorectal Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016
  • Colorectal Cancer - Pipeline by EirGenix Inc., H1 2016
  • Colorectal Cancer - Pipeline by Eisai Co., Ltd., H1 2016

List of Figures

  • Number of Products under Development for Colorectal Cancer, H1 2016
  • Number of Products under Development for Colorectal Cancer - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top